Vivani Medical — Third Quarter 2026 Earnings Summary

Vivani Medical reported a net loss of $7.3 million for the third quarter ended September 30, 2026, driven by increased research and development expenses related to its Biopharm Division. The company anticipates announcing top-line results from its SLIM-1 Phase 1 trial for the NPM-139 semaglutide implant later in November 2026. Additionally, the merger between Cortigent and ClearOne remains pending final regulatory approvals required to establish Cortigent as a standalone Nasdaq-traded entity. Vivani's cash and cash equivalents totaled $15.5 million as of the end of the quarter, down from $20.8 million in the previous quarter.